A carregar...
Tumor mutational burden in non-small cell lung cancer—the pathologist’s point of view
In non-small cell lung cancer (NSCLC), the pathologist has contributed to the development of personalized medicine from the determination of the right histological type to EGFR and ALK/ROS1 molecular screening for targeted therapies. With the development of immunotherapies, pathologists intervene fo...
Na minha lista:
| Publicado no: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6249617/ https://ncbi.nlm.nih.gov/pubmed/30505716 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2018.09.26 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|